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Summary
Aim.— To estimate the prevalence of triglyceride and/or high density lipoprotein cholesterol
(HDL-C) disorders and their relationships with other cardiovascular risk factors among patients
with dyslipidaemia on lipid-lowering therapy.
Methods.— In this cross-sectional study in dyslipidaemic patients receiving lipid-lowering ther-
apy, lipid disorders were deﬁned as triglyceride greater than 1.5 g/L, HDL-C lesser than 0.4 g/L
and low-density lipoprotein cholesterol (LDL-C) above the recommended concentration accord-
ing to French guidelines. Based on these disorders, patients were classiﬁed into four groups:
group 1, no lipid disorders; group 2, low HDL-C and/or high triglyceride concentration with
normal LDL-C; group 3, isolated elevated LDL-C; and group 4, elevated LDL-C and low HDL-C
and/or high triglyceride. Patients’ cardiovascular risk levels were compared across groups.
Results.— Among the 2727 patients (mean age 64.7 years, 46.7% women), 28% did not reach
the target LDL-C concentration as deﬁned by French guidelines. Prevalence rates of high
triglyceride and low HDL-C were 27.2 and 10.3%, respectively. Over half (51.2%) of the patients
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were in group 1, 20.5% were in group 2, 16.2% in group 3 and 12.1% in group 4. Among patients
meeting the target LDL-C, those with high triglyceride and/or low HDL-C exhibited a signiﬁcantly
higher number of risk factors (1.83 vs 1.68, p < 0.001). Smoking, diabetes and hypertension were
associated separately with low HDL-C and/or high triglyceride (p = 0.01, p < 0.0001, p = 0.03,
respectively). Conversely, these associations were not observed in patients who did not achieve
the target LDL-C, with the exception of smoking (p < 0.0001).
Conclusion.— HDL-C and triglyceride disorders are relatively frequent among treated patients,
particularly when cardiovascular risk level increased.
© 2008 Elsevier Masson SAS. All rights reserved.
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Résumé
Introduction.— L’objectif était d’estimer chez des patients dyslipidémiques traités la
fréquence de l’hypertriglycéridémie et des taux bas en HDL-C, et leur association avec les
autres facteurs de risque cardiovasculaire.
Méthodes.— Une étude transversale (REALITY II) a été réalisée en médecine générale auprès
de patients sous hypolipémiant. À partir des anomalies étudiées en triglycérides (> 1,5 g/L),
HDL-C (< 0,4 g/L) et LDL-C (non-atteinte de l’objectif thérapeutique selon les critères de
l’Afssaps—2005), quatre groupes de patients ont été identiﬁés : 1 — absence d’anomalie
lipidique résiduelle, 2 — triglycérides élevés et/ou HDL-C bas avec LDL-C normal, 3 — anomalie
isolée du LDL-C, 4 — anomalie du LDL-C avec triglycérides élevés et/ou HDL-C bas. Le niveau
de risque cardiovasculaire des patients a été comparé entre ces quatre groupes.
Résultats.— Sur 2727 patients (âge moyen = 64,7, 47 % de femmes), 28 % avaient un LDL-C élevé,
27,2 % des triglycérides élevés et 10,3 % un taux bas de HDL-C. Les fréquences respectives des
quatre groupes étaient 51,2, 20,5, 16,2 et 12,1 %. Parmi les patients avec LDL-C à l’objectif,
ceux du groupe 2 présentaient davantage de facteurs de risque cardiovasculaire non lipidiques
que les patients du groupe 1 (1,83 vs 1,63, p = 0,0004), comme le tabagisme (p = 0,01), le diabète
(p < 0,0001) ou l’hypertension artérielle (p = 0,03). Les différences étaient non signiﬁcatives
entre les patients des groupes 3 et 4, sauf pour le tabagisme (p < 0,0001).
Conclusion.— L’hypertriglycéridémie et les taux bas en HDL-C sont fréquents chez les patients
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bbreviations
DL-C high-density lipoprotein cholesterol
DC-C low-density lipoprotein cholesterol
ackground
igh concentration of LDL-C is a well-known cardiovascular
isk factor. Many studies have shown that despite the use of
tatins, it can be difﬁcult to achieve the therapeutic objec-
ives for LDL-C in line with ofﬁcial recommendations [1,2] in
veryday clinical practice [3]. Results from certain studies
uggest that abnormal levels of HDL-C and triglycerides have
n impact on cardiovascular disease, particularly when the
wo are found together [4—6]. Little information is avail-
ble, however, about these abnormalities.
One recent French study involving a representative pop-
lation of subjects with no history of cardiovascular disease
r of lipid-lowering treatment showed that the prevalence
f low HDL-C and high triglycerides was by no means neg-
igible [7]. An earlier study suggested that there was an
ssociation between the presence of abnormal concentra-
ions of LDL-C and/or HDL-C and triglycerides and greater
ardiovascular risk [8]. The principal aim of the present
tudy was to estimate the prevalence of abnormal levels of
riglyceride and/or HDL-C in a population of patients with
ﬁ
l
t
c
ament en présence de facteurs de risque cardiovasculaires.
s droits réservés.
yslipidaemia followed by their general practitioner (GP).
he association between the presence of these abnormal-
ties and the level of cardiovascular risk was a secondary
bjective.
ethods
tudy population
cross-sectional observational study (REALITY II) was con-
ucted between July and September 2006 among patients
reated with lipid-lowering drugs (statins, ﬁbrates, ezetim-
be) and followed-up by GPs afﬁliated to the Cegedim France
etwork. Details of the study methods have been described
reviously [9].
To be eligible for inclusion, patients must have recently
ndergone a complete analysis of their lipid status (LDL-
, HDL-C and triglyceride), be receiving lipid-lowering
herapy and have had their lipid status analysed during
he six months before inclusion. Patients were ineligible
or inclusion if their lipid treatment had been modi-
ed during the three months before the most recent
ipid analysis. Patients were recruited during a consul-
ation with their GP, after providing written informed
onsent. The protocol of the REALITY II study was
pproved by the Commission Nationale Informatique et
ic d
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Libertés, the government body responsible for data protec-
tion.
Data collected
Information concerning cardiovascular risk factors and lipid
analyses was collected by the GPs at the end of the consul-
tation using a computerized questionnaire. The treatments
prescribed were available on the Cegedim Longitudinal
Patient Database.
Lipid abnormalities
Abnormalities in HDL-C and triglyceride concentrations were
deﬁned as HDL-C lesser than 0.4 g/L [1] and triglyceride
greater than 1.5 g/L [10]. In our study, LDL-C was considered
abnormal when the therapeutic objective according to the
2005 Agence Franc¸aise de Sécurité Sanitaire des Produits de
Santé (Afssaps) criteria for LDL-C had not been achieved [1].
Patients were categorized into one of four groups
according to the lipid abnormalities found: normal lipid con-
centrations (group 1), high triglyceride and/or low HDL-C
with normal LDL-C (group 2), isolated abnormal LDL-C (group
3), and abnormal LDL-C with high triglyceride and/or low
HDL-C (group 4).
Cardiovascular risk
We used the cardiovascular risk factors deﬁned by the
Afssaps [1]: age (≥ 60 years for women; ≥ 50 years for
men), current smoking or cessation within the previous
three years, arterial hypertension, type 2 diabetes, fam-
ily history of early myocardial infarction or sudden death
and HDL-C lesser than 0.4 g/L. Arterial hypertension was
deﬁned as either high blood pressure recorded in the
database (systolic≥ 140mmHg and/or diastolic≥ 90 mmHg)
or by the prescription of antihypertensive drugs (direct
antihypertensive agent, diuretics, calcium-channel block-
ers, angiotensin-converting enzyme inhibitors or angiotensin
II receptor blockers, beta-blockers). Diabetes was deﬁned as
the diagnosis of diabetes on the database (or of one of the
associated complications) or by the prescription of an oral
antidiabetic drug or insulin.
Cardiovascular risk level was evaluated using two differ-
ent approaches.
Classes of risk deﬁned by the Afssaps
The Afssaps distinguishes between ﬁve classes of patients,
according to the number of cardiovascular risk factors other
than dyslipidaemia: no additional risk factors, one risk fac-
tor, two risk factors, more than two risk factor and high risk.
For the ﬁrst four categories, one risk factor was removed
with HDL-C greater than 0.6 g/L. The ‘‘high-risk’’ category
comprised patients with a history of cardiovascular disease,
patients with high-risk type 2 diabetes (diabetes with at
least two additional risk factors and/or renal failure), and
primary prevention patients with a greater than 20% risk
of an adverse coronary event in the forthcoming 10 years
according to the Framingham equation [11].Sum of non-lipid risk factors
In this study, as low HDL-C was both a cardiovascular risk
factor taken into account in the Afssaps classiﬁcation and
one of the lipid abnormalities studied, we also compared the
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our groups of patients according to the cumulative number
f these cardiovascular risk factors without HDL-C.
tatistical analyses
he prevalence of the four groups of lipid abnormalities
as deﬁned above) was determined (Fig. 1). Complemen-
ary analyses were carried out by considering separately
atients receiving statin monotherapy and those under
brate monotherapy (Figs. 2 and 3). Then, the four groups
f patients were compared for each risk factor, for the Afss-
ps class of risk and for the number of non-lipid risk factors
Table 2).
To determine the impact of abnormal HDL-C and/or
riglyceride concentration independently of achieving the
herapeutic objectives for LDL-C, speciﬁc comparisons were
un in groups 1 and 2 (‘‘normal lipids’’ versus ‘‘high triglyc-
ride and/or low HDL-C with normal LDL-C’’) on the one
and, and groups 3 and 4 on the other (‘‘isolated abnormal
DL-C’’ vs ‘‘abnormal LDL-C with high triglyceride and/or
ow HDL-C’’). Chi2, Wilcoxon and Kruskal-Wallis tests were
sed for all of the analyses using SAS® version 9.1 software.
he threshold for signiﬁcance was p < 0.05.
esults
atient characteristics
ver half of the 2727 patients were men (53.3%). Almost
0% of patients were at high cardiovascular risk. Most
atients were receiving monotherapy with either a statin
r a ﬁbrate (Table 1). There was a statistically signiﬁcant
ifference between the four groups with regard to distri-
ution of treatments (p < 0.0001) but we found no major
linical differences. Statin monotherapy was used slightly
ess frequently in patients with an abnormal LDL-C concen-
ration plus other abnormalities (group 4), whereas ﬁbrate
onotherapy or combination lipid-lowering drugs tended to
e used more frequently. Patients on statin monotherapy
ere more likely to have isolated abnormal LDL-C concen-
ration.
ipid concentrations and abnormalities
he mean (standard deviation) overall lipid concentrations
ere 1.21 (0.35), 0.57 (0.16) and 1.30 (0.71) g/L for LDL-C,
DL-C and triglyceride, respectively. Given the thresholds
elected, more than one-quarter (27.2%) of patients had
igh triglyceride concentrations while 10.3% had low HDL-C.
round 28% of patients did not reach the therapeutic target
or LDL-C.
Overall, almost one-third of patients presented abnor-
al concentrations of HDL-C and/or triglyceride (groups 2
nd 4, Fig. 1). Approximately 12% of patients presented
hese abnormalities even though they had not achieved
he therapeutic target for LDL-C (group 4). In contrast,
ore than half of the patients had no lipid abnormal-
ties while on treatment (Fig. 1). No major changes in
esults were observed when analyses were restricted to
atients receiving a statin or a ﬁbrate in monotherapy
Figs. 2 and 3).
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Figure 1. Combination of lipid abnormalities for the overall population (n = 2727).
Figure 2. Combination of lipid abnormalities for patients on statin monotherapy (n = 1910).
F te m
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1igure 3. Combination of lipid abnormalities for patients on ﬁbrabnormal lipid levels and cardiovascular risk
atients with isolated abnormal concentrations of LDL-C
group 3) were older than those in the other groups. Group
(normal lipid levels) had a higher proportion of women
(
t
a
t
(onotherapy (n = 664).Table 2). Women were also less likely to have abnormal
riglyceride and/or HDL-C concentrations, notably in the
bsence of abnormal LDL-C (group 2 vs group 1, p < 0.0001);
he difference between groups 3 and 4 was not signiﬁcant
p = 0.12). Considered individually, the cardiovascular risk
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Table 1 Patient characteristics (n = 2727).
n (%) or mean (standard deviation)
Men 1453 (53.3)
Age (years) 64.7 (11.0)
Cardiovascular risk factors
Age: men ≥ 50 years, women ≥ 60 2219 (81.4)
Smoking: current or cessation within 3 years 365 (13.4)
Type 2 diabetes 605 (22.2)
Arterial hypertension 1626 (60.0)
Family history of early myocardial infarction or sudden death 386 (14.2)
History of cardiovascular disease 745 (27.3)
Level of cardiovascular risk (Afssaps)a
No additional risk factors 398 (14.6)
1 risk factor 637 (23.4)
2 risk factors (18.6)
> 2 risk factors 119 (4.4)
High risk 1065 (39.1)
Lipid-lowering treatment
Statin monotherapy 1910 (70.0)
Fibrate monotherapy 664 (24.3)
Statin + lipid-lowering agent other than a ﬁbrateb 74 (2.7)
Fibrate + lipid-lowering agent other than a statinc 39 (1.4)
Other treatments or associationsd 40 (1.5)
a Excluding dyslipidaemia.
b Statin + ezetimib (n = 20), statin + cholestyramine (n = 3), statin + benﬂuorex (n = 34), statin + omega-3 (n = 3), statin + vitamin E
(n = 10), atorvastatin + simvastatin + benﬂuorex (n = 1), atorvastatin + simvastatin (n = 1), atorvastatin + rosuvastatin (n = 1), atorvas-
tatin + ezetimib + benﬂuorex (n = 1).
c Fibrate + ezetimib (n = 3), ﬁbrate+cholestyramin (n = 5), ﬁbrate + benﬂuorex (n = 21), ﬁbrate+omega-3 (n = 3), ﬁbrate + vitamin E (n = 6),
ﬁbrate + vitamin E + benﬂuorex (n = 1).
d Ezetimib (n = 19), simvastatin/ezetimib (n = 15), ﬁbrate + statin (n = 2), ezetimib+vitamin E (n = 2), nicotinic acid + benﬂuorex (n = 1),
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factors varied principally according to whether or not the
therapeutic target for LDL-C had been achieved (groups 3
and 4 vs groups 1 and 2, Table 2). Two factors appeared to
be associated with the presence of abnormal concentrations
of HDL-C and/or triglyceride: smoking and diabetes. There
were more current or recent former smokers among patients
with abnormal concentrations of HDL-C and/or triglyceride.
This was true for both patients with normal concentrations
of LDL-C (group 2 vs group 1, p = 0.01) and with abnormal
LDL-C (group 4 vs group 3, p < 0.0001).
The proportion of diabetic patients was greater in group
2 than in group 1 (p < 0.0001), and in group 4 compared to
group 3, even though the difference between groups 3 and
4 was not signiﬁcant (p = 0.09). The proportion of diabetic
patients in group 4 was threefold higher than that in group
1. Patients with abnormal triglyceride and/or HDL-C and
normal LDL-C concentrations were more likely to present
arterial hypertension than patients with a normal lipid sta-
tus (group 2 vs 1, p = 0.03). This was not the case for group
3 compared to group 4 (Table 2).Level of cardiovascular risk (Afssaps guidelines)
The proportion of low-risk categories was greater (0 or 1 risk
factor other than dyslipidaemia) in group 1 (57.9%), and a
r
o
p
w
pesser degree, in group 2 (35.2%). In contrast, these patients
ere in the minority in groups 3 and 4 (4.5 and 3.0%, respec-
ively). This is in keeping with the fact that groups 3 and
included essentially patients at high cardiovascular risk
Table 2).
Comparison of groups 1 and 2 showed that there was
greater proportion of high-risk patients in the low HDL-
and/or high triglyceride group (p < 0.0001). In contrast,
here were more high-risk patients in the isolated abnormal
DL-C group (group 3) compared with in group 4 (p < 0.01).
here were also more patients with history of cardiovascular
isease in group 3.
umber of non-lipid cardiovascular risk factors
he number of non-lipid cardiovascular risk factors
ncreased across the groups, especially in patients who
ad not achieved the therapeutic target for LDL-C.
mong those who achieved the target, the number of
isk factors also increased signiﬁcantly in the presence
f abnormal HDL-C or triglyceride (groups 1 and 2,
= 0.0004). The difference was not signiﬁcant in patients
ho had not achieved the target (groups 3 and 4,
= 0.15).
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Table 2 Patient characteristics and comparison of cardiovascular risk between groups.
Group 1a Group 2a Group 3a Group 4a p
n = 1395 n = 560 n = 443 n = 329
LDL-cholesterol (g/L) 1.14 (0.30) 1.09 (0.32) 1.38 (0.33) 1.47 (0.39) < 0.0001
HDL-cholesterol (g/L) 0.62 (0.15) 0.50 (0.15) 0.59 (0.14) 0.47 (0.14) < 0.0001
Triglycerides (g/L) 0.96 (0.28) 1.92 (0.83) 1.05 (0.27) 2.00 (0.91) < 0.0001
Age (years) 65.0 (10.7) 61.8 (11.1) 67.7 (10.6) 63.8 (11.3) < 0.0001
Women 55.0 40.5 38.6 33.1 < 0.0001
Lipid-lowering treatment
Statin monotherapy 69.5 70.0 75.8 64.4 < 0.0001
Fibrate monotherapy 26.1 20.7 21.4 27.4
Other 4.4 9.3 2.7 8.2
Level of cardiovascular risk (Afssaps)
No additional risk factors 23.0 12.3 1.3 0.6 < 0.0001
1 risk factor 34.9 22.9 3.2 2.4
2 risk factors 19.8 27.3 8.3 12.8
> 2 risk factors 2.0 9.1 3.2 7.9
High risk 20.3 28.4 84.0 76.3
Details for high-risk patients
High-risk primary prevention patientsb 3.9 8.2 26.2 31.3
History of isolated cardiovascular
disease
12.4 12.3 49.0 34.3
History of cardiovascular disease and
high-risk diabetes
3.9 7.9 8.8 10.6
Risk factors
Diabetes 13.2 21.2 36.6 42.5 < 0.0001
Age: men ≥ 50 years, women ≥ 60
years
79.3 76.4 91.2 85.4 < 0.0001
Arterial hypertension 53.5 58.7 72.2 70.2 < 0.0001
Family history of early myocardial
infarction or sudden death
11.8 12.3 19.6 20.1 < 0.0001
Smoking (current or cessation within
the previous 3 years)
10.0 13.9 14.2 25.5 < 0.0001
History of cardiovascular disease 16.3 20.2 57.8 45.0 < 0.0001
Number of non-lipid risk factorsc 1.68 (0.88) 1.83 (0.96) 2.34 (0.91) 2.44 (0.95) < 0.0001
Results are given as per cent or mean (standard deviation).
a Group 1: Normal lipid concentration; group 2: High triglyceride and/or low HDL-C with normal LDL-C; group 3: Isolated abnormal
LDL-C; group 4: Abnormal LDL-C with high triglyceride and/or low HDL-C.
b Risk of experiencing an adverse coronary event in the coming 10 years greater than 20% (Framingham equation) and/or high risk
diabetes.
0 ye
prem
D
P
H
A
n
i
l
q
A
H
f
g
d
w
s
c
g
p
l
—
rc Except dyslipidaemia and HDL-C, and including women aged 6
smoking, arterial hypertension, type 2 diabetes, family history of
iscussion
revalence of abnormal concentrations of
DL-C and/or triglyceride
bnormal concentrations of triglyceride and HDL-C were
ot unusual in patients treated with lipid-lowering drugs
n general medicine. Approximately 10% of patients had a
ow concentration of HDL-C (< 0.4 g/L) and more than one-
uarter had high concentrations of triglyceride (> 1.5 g/L).
lmost one-third of the patients in our study presented low
DL-C and/or high triglyceride, with the therapeutic target
or LDL-C either achieved (20.5%, group 2) or not (12.1%,
roup 4).
d
>
tars and over or men aged 50 years and over, current or recent
ature death or early adverse coronary events.
Direct comparisons with Ferrières et al.’s study [7] are
ifﬁcult because the thresholds for lipid concentrations
ere different as were the characteristics of the populations
tudied. It is possible to conclude, however, that abnormal
oncentrations of HDL-C and triglyceride identiﬁed in the
eneral population [7] are also common in dyslipidaemic
atients treated with lipid-lowering drugs. A high preva-
ence of low HDL-C (< 0.4 for men and < 0.5 g/L for women)
that is 40% of women and 33% of men —has also been
eported in a population of treated patients with severe
yslipidaemia (total cholesterol > 2 g/L and/or triglyceride
1.8 g/L) followed-up in a specialized institution [12].
In our study, we found no major differences in the dis-
ribution of lipid abnormalities when we compared patients
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on statin monotherapy with those on ﬁbrate monotherapy
(Figs. 1—3). These results are difﬁcult to interpret as the
nature and severity of the abnormalities before treatment
are unknown.
Abnormal concentrations of triglyceride
and/or HDL-C and cardiovascular risk level
Overall, our results are in line with those of an earlier study
in which we reported an association between the presence
of mixed lipid abnormalities and high level of cardiovascu-
lar risk, even though direct comparison of the results is not
possible because different reference values were used [8].
In our present study, level of cardiovascular risk varied
particularly according to whether the therapeutic target for
LDL-C had been achieved (Table 2). These ﬁndings could be
explained by the choice of the Afssaps criteria to deﬁne
normal concentrations of LDL-C. Indeed, the higher the
patient’s level of cardiovascular risk, the lower the ther-
apeutic target for LDL-C (according to the Afssaps criteria).
As a result, the greater the risk, the more difﬁcult it is to
achieve the therapeutic objectives and thus to be placed
in group 1 or 2. This led us to carry out stratiﬁed analy-
ses in patients according to the therapeutic objectives for
LDL-C (group 1 vs 2) and in those who had not achieved
the therapeutic objectives (group 3 vs 4), in order to study
the association between level of cardiovascular risk and
HDL-C and or TG lipid abnormalities. Overall, independently
of LDL-C, our results suggest the existence of an associa-
tion between cardiovascular risk factors and presence of
abnormal triglyceride and/or HDL-C concentration. There
were more diabetic patients, current or former smokers
and hypertensive patients in group 2 than in group 1. There
were also more current or recent former smokers and, to a
lesser degree, diabetic patients in group 4 than in group 3
(patients presenting isolated abnormal LDL-C). The associa-
tion between diabetes and low HDL-C, and between diabetes
and high triglyceride concentration, has been described pre-
viously [13], as has the higher frequency of abnormal HDL-C
and triglyceride concentrations in patients with diabetes or
hypertension and in smokers [14].
In patients with abnormal LDL-C concentrations (groups 3
and 4), the association between level of cardiovascular risk
and presence of high triglyceride and/or low HDL-C concen-
tration tended to be less marked. This difference in the
results, compared with that between patients in groups 1
and 2, must be interpreted with caution. Indeed, it is pos-
sible that the already high level of cardiovascular risk in
patients in groups 3 and 4 make it difﬁcult to show any
association between these levels of risk and the presence
of abnormal HDL-C and/or triglyceride concentration. Fur-
thermore, fewer patients were at high risk (according to the
Afssaps criteria) in group 4 than in group 3. This result could
be explained by the greater proportion of patients with a
history of cardiovascular disease in the group with isolated
hypercholesterolemia compared to those with mixed disor-
ders (57.8 vs 45.0%, p < 0.001). Moreover, patients in group 3
were older than those in group 4. With this in mind, it would
be interesting to check our results against other references
for abnormal lipid concentrations, notably for LDL-C.
Other methodological limitations of our study must be
highlighted. First, interpretation of the results relative to
C
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he cardiovascular risk level (according to the Afssaps crite-
ia) was questionable; abnormal HDL-C concentration, which
e included among the lipid abnormalities, was one of the
isk factors in this classiﬁcation. Because of this, we studied
n parallel the total number of non-lipid risk factors. As there
as no analysis of lipid concentrations before treatment, it
s impossible to determine the nature and severity of the
nitial dyslipidaemia (LDL-C, HDL-C, triglyceride, mixed). It
as not possible to evaluate the impact of lipid-lowering
reatments on the initial abnormalities. Moreover, certain
ardiovascular risk factors such as obesity, alcohol consump-
ion or sedentary lifestyle were not taken into account.
owever, associations between these factors and the pres-
nce of low HDL-C concentration [7] and the combination of
ow HDL-C and high triglyceride concentrations have been
dentiﬁed already [14]. We did not have any data on the
ietary habits of the patients either. Finally, given the cross-
ectional nature of the study, it was not possible to study the
ombined impact of the various lipid abnormalities on the
nset of heart disease.
tudy implications
ailure to treat low HDL-C or high triglyceride can have
onsequences for the heart. Low HDL-C concentration is a
redictor of adverse cardiovascular events [15—17] or death
18] in patients with a high level of cardiovascular risk.
he involvement of triglycerides in the onset of coronary
rtery disease is more controversial [19], even though cer-
ain studies suggest they do play a role [20], notably in
ssociation with low HDL-C concentration [4]. Although cor-
ection of high LDL-C must remain a priority, physicians must
ot neglect abnormal levels of triglyceride and HDL-C. As
uggested in our study, the higher the level of cardiovas-
ular risk, the higher the proportion of patients with these
bnormalities.
First, as with LDL-C, the priority is to ensure that patients
dopt a healthy lifestyle, in particular by following an appro-
riate diet. The ﬁght against a sedentary lifestyle is also an
ssential element. The beneﬁcial impact of physical activ-
ty has been demonstrated with regard to both triglycerides
21,22] and HDL-C [22,23]. When necessary, advertising
ampaigns to alert patients to the risks could be useful.
hese measures go hand in hand with smoking cessation and
reatment of associated risk factors such as diabetes and
rterial hypertension. Then, should these initial measures
rove to be insufﬁcient even though they are respected, it
ay be necessary to adapt or reinforce lipid-lowering treat-
ent on a case-by-case basis. Therapeutic issues may differ
etween patients on statin therapy, with its more limited
ffect on triglyceride and HDL-C concentrations (compared
ith LDL-C), and for those receiving a ﬁbrate, as this class is
ess efﬁcient than statins on LDL-C, but more effective with
egard to the ﬁrst two parameters.onclusion
he prevalence of abnormal concentrations of HDL-C and/or
riglyceride is relatively high in patients treated with lipid-
owering drugs. The results of this study suggest that
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atients who present this type of abnormalities tend to have
higher level of cardiovascular risk, particularly when they
chieve therapeutic target for LDL-C. It would be useful to
erify the robustness of our results using other criteria for
ipid abnormalities, notably with regard to LDL-C.
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